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Summary 
Ovarian cancer is the most lethal gynecologic malignancy. Recently, several 
molecularly targeted anticancer agents have been developed for ovarian cancer; 
however, its prognosis has remained extremely poor. The development of molecularly 
targeted therapy, as well as companion diagnostics, is required to improve outcomes for 
patients with ovarian cancer. In this study, to identify microRNAs involved in the 
progression of ovarian cancer we analyzed serum microRNAs in patients with ovarian 
cancer using microRNA array and qRT-PCR and examined the anticancer properties of 
microRNA expression in ovarian cancer cells. In patients with ovarian cancer, high 
expression of miR-135a-3p in serum samples was significantly associated with 
favorable clinical prognosis. Expression of miR-135a-3p was significantly decreased in 
patients with ovarian cancer compared with patients with ovarian cysts or normal 
ovaries. In SKOV-3 and ES-2 human ovarian cancer cells, enhanced expression of 
miR-135a-3p induced drug sensitivity to cisplatin and paclitaxel and suppressed cell 
proliferation and xenograft tumor growth. These findings suggest that miR-135a-3p 
may be considered as a biomarker and a therapeutic agent in ovarian cancer.  
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1. Introduction 
microRNAs (miRNAs) are small non-coding RNAs (18–22 nt) that modulate 
gene expression. They contribute to many biological processes including cell 
proliferation, differentiation, and death, and are also involved in pathologies such as 
cancer, diabetes, cardiovascular, and gynecologic diseases (1-3). miRNAs are present in 
exosomes in various biofluids such as plasma, serum, urine, semen, menstrual blood, 
and amniotic fluid, and consequently have been proposed as ideal candidates for disease 
biomarkers (4). Recently, they have also been proposed as drug targets for many human 
diseases (5-7). 
Ovarian cancer, the most lethal malignancy in gynecologic oncology, is 
characterized by an extremely poor prognosis from the extensive spread of ovarian 
cancer cells into the peritoneal cavity (8). Cytoreductive surgery and the introduction of 
platinum plus taxane-based chemotherapies in the past decade have improved survival 
in patients with epithelial ovarian cancer (9,10). In the ICON7 trial, standard 
chemotherapy with bevacizumab did not increase overall survival in patients with newly 
diagnosed ovarian cancer, although it did improve progression-free survival (PFS) and 
peritoneal fluid retention (11). In clinical trials, PARP inhibitors did not improve overall 
survival, whereas PFS was significantly prolonged (12). Accordingly, the development 
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of molecularly targeted therapeutics and their diagnostic companion tests is required to 
improve these poor outcomes. 
Many reports have investigated alterations in miRNA levels as biomarkers in 
ovarian cancer (13-16). Currently, inconsistencies in results do not support the use of 
miRNA as a diagnostic tool in tissue or serum specimens from patients with ovarian 
cancer. In many studies, miRNA expression in ovarian cancer tissue was compared with 
that in normal ovarian tissue. However, typically, the ovarian epithelium was not 
microdissected or scraped, meaning that the difference in miRNA expression between 
ovarian cancer tissue and ovarian stroma was evaluated, even though ovarian stroma 
compromises more than 95% of the ovarian tissue in normal specimens (14). Moreover, 
because of major differences in serum miRNA expression between malignant and 
benign tumor status, comparisons of normal versus tumor tissue are considered 
inadequate to identify miRNAs regulating carcinogenesis. To explore key miRNAs as 
biomarkers for cancer progression, proper selection and high quality tissue or serum 
specimens are essential.  
In this study, to identify candidate miRNAs as biomarkers and for therapeutic 
intervention in the progression of ovarian cancer, we performed miRNA array analysis 
of sera between patients with poor and favorable prognosis and evaluated the clinical 
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significance of these miRNAs and tumor properties after their transfection into ovarian 
cancer cells. Our data identified miR-135a-3p as a miRNA that regulates tumor 
potential through modulating drug sensitivity and tumor growth. 
 
2. Material and methods 
2.1. Serum, peritoneal fluid, and tissue samples 
All clinical samples were obtained from Fukuoka University Hospital (n=88, 
Fukuoka, Japan) or Kyusyu University Hospital (n=98, Fukuoka, Japan). Serum 
samples were placed at 4°C no more than 24 h after collection and separated from clots 
by centrifugation at 3,000 rpm for 20 min at 4°C. Peritoneal fluids and tissue samples 
were collected at primary surgery and placed on ice immediately. Peritoneal fluids were 
centrifuged at 3,000 rpm for 20 min at 24°C to separate debris within 1 h of collection. 
Tissue samples were soaked in RNAlater solution (Life Technologies) and incubated at 
4°C overnight (for ≤24 h). All sera, peritoneal fluids, and tissue samples were stored at 
80°C for further RNA extraction. 
Twelve patients with ovarian cancer (Supplementary Table 1) were enrolled 
for miRNA array analysis. They were divided into two groups: the poor prognosis group 
(group A) consisted of six patients who had recurrence of ovarian cancer within 6 
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months after completion of primary treatment including both platinum and taxane, and 
the favorable prognosis group (group B) included six patients with ovarian cancer who 
had no recurrence or recurrence more than 6 months after completion of primary 
treatment containing both platinum and taxane.  
For real-time PCR (qPCR) of the miRNAs, serum obtained from 98 patients 
(group C) with ovarian cancer (Supplementary Table 2) was analyzed to assess the 
relationship between miRNA expression and PFS. To assess expression of miR-135a-3p 
and its target genes, serum and tissue samples were simultaneously examined in 47 
patients with ovarian cancer (group D; Supplementary Table 2). For 17/47 patients, 
miR-135a-3p in peritoneal fluid was also examined using qPCR. Additionally, 
miR-135a-3p expression was also examined as controls in sera from seven patients with 
benign gynecologic diseases (mean age ± SD, 65.2 ± 4.8), in sera and peritoneal fluids 
from 24 patients with benign ovarian cysts (age: 38.0 ± 17.6), in tissues from five 
patients with endometrial cancer in clinical stage I (group E; Supplementary Table 2), 
and in five RNA samples of normal ovary tissue obtained from OriGene Technologies 
(Catalog No: CR561675, CR561070, CR561721, CR560512, CR562355; Kanagawa, 
Japan) . 
The present study was approved by the Ethics Committee of Fukuoka 
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University Hospital (Fukuoka, Japan) and Kyusyu University Hospital (Fukuoka, 
Japan). All individuals provided written informed consent. Sera, peritoneal fluid, or 
tissue samples from ovarian cancer patients were collected from 2009–2015 at Fukuoka 
University and Kyusyu University. Clinical and pathologic information for ovarian 
cancer patients was collected from clinical records. Tumors were staged using the 
International Federation of Gynecology and Obstetrics (FIGO) staging system. All 
ovarian cancer patients had been diagnosed histopathologically without radiotherapy or 
chemotherapy prior to study participation. These patients included newly diagnosed 
cases and those undergoing follow-up. 
 
2.2. Total RNA extraction 
 Total RNA was isolated from sera and peritoneal fluids using QIAzol reagent 
(Qiagen, Tokyo, Japan) and the miRNeasy Serum/Plasma Kit (Qiagen). Briefly, 300 µl 
of serum or peritoneal fluids sample was mixed with 1.5 ml of Qiazol Lysis Reagent 
and incubated at room temperature for 5 min. As a spike-in control, 3.5 µl of 1.6 × 108 
copies/µl miR-39-3p from Caenorhabditis elegans (Cel-miR-39-3p) was added. RNA 
was purified according to the manufacturer’s protocol and eluted in 38 µl of RNase-free 
water. Total RNA was isolated from tissues using TRIzol reagent (Invitrogen) according 
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to the manufacturer’s protocol. RNA concentrations and 260 to 280 nm absorbance 
ratios were measured using a Nano Drop 1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, DE). 
 
2.3. Reverse transcription (RT) and qPCR 
For cDNA generation for miRNAs, 5 µl of total RNA was used for each RT 
reaction with specific primers for miR-135a-3p, miR-630, miR-1207, Cel-miR-39-3p, 
and RNU6B, according to the manufacturer’s protocol (Life Technologies). For cDNA 
generation from mRNA, total RNA from tissues was reverse transcribed using 
PrimeScript II reverse transcriptase (Takara Bio, Otsu, Shiga, Japan) according to the 
manufacturer’s protocol. The RT product was stored at 80°C. 
qPCR was subsequently performed with an ABI Prism 7500 Fast Real-Time 
PCR system (Applied Biosystems, Foster City, CA) in a 15- or 20-µl reaction with 
TaqMan Universal Master Mix (Applied Biosystems). Amplification was carried out by 
denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 
60 s. 
Exponential processes (Ct-values) of miRNAs from serum and peritoneal 
fluids were converted to linear comparisons relative to the control group and normalized 
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to the spike-in Cel-miR-39-3p using 2-∆∆Ct methods. Gene expression was analyzed 
using the difference in cycle threshold (2-∆∆Ct) method. Ct values of tissue miRNA were 
normalized to RNU6B, and those of mRNA were normalized to GAPDH as internal 
controls. ∆∆CT values were plotted and statistical analysis was performed using 
GraphPad Prism (GraphPad Software, CA, USA). The TaqMan primer and probes 
(Applied Biosystems) used were as follows: miR-135a-3p, 002232; miR-630, 001563; 
miR-1207, 002826; cel-miR-39; 000200; RNU6B, 001093; BIRC3, Hs00985031_g1; 
GABRA3, Hs00968132_m1; SPANXB1/2, Hs02387419_gH; TMPRss15, 
Hs00160491_m1; NCAM2, Hs00189850_m1; SYT4, Hs01086433_m1; C9orf152, 
Hs00418117_m1; IL1RAP, Hs00895050_m1; RERG, Hs01556349_m1; PAIP1, 
Hs01925976_s1; PPP2R2B, Hs00270227_m1; and GAPDH, Hs02758991. 
 
2.4. miRNA microarray and expression array analysis 
 miRNA microarray profiling was carried out using Agilent Human miRNA 
Microarray (Agilent Technologies, Japan), containing probes for 1,523 human and 364 
viral miRNAs from the Sanger database. Total RNA was extracted as above and purified 
using the SV Total RNA Isolation System (Promega). cRNA was amplified and labelled 
with Cy3 using a Low input Quick Amp Labeling Kit (Agilent Technologies). cRNA was 
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hybridized to a 60 K 60-mer oligomicroarray (SurePrint Human miRNA Microarray 
Release 16.0, 8 × 60 K; Agilent Technologies) according to the manufacturer’s 
instructions. Hybridized microarray slides were scanned using an Agilent scanner. 
Relative hybridization intensities and background hybridization values were calculated 
using Feature Extraction Software version 9.5.1.1 (Agilent Technologies). Scanned 
images were analyzed with Feature Extraction Software 9.5.1.1 (Agilent) using default 
parameters to obtain background subtracted and spatially detrended Processed Signal 
intensities. Raw signal intensities and flags for each probe were calculated from 
hybridization intensities and spot information according to procedures recommended by 
Agilent Technologies using Flag criteria in GeneSpring Software. The complete data set 
may be accessed at NCBI-Gene Expression Omnibus (accession GSE79943). 
 Expression array profiling was carried out using the Affymetrix Human Gene 
2.0 ST Array as described in the manufacturer’s protocol. The analysis was conducted 
using SKOV-3 and ES-2 cells with forced expression of miR-135a using an expression 
vector. Total RNA extraction was performed using the RNeasy Plus Mini Kit (Qiagen) 
according to the manufacturer’s instructions. cDNA synthesis, amplification, and 
labeling with biotin were performed with the WT PLUS Reagent Kit (Affymetrix). RNA 
Integrity Number (RIN) values of extracted RNA were determined with an Agilent 2100 
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Bioanalyzer (Agilent Technologies). To ensure optimal data quality, only samples with 
RIN ≥9.0 were included in the analysis. Following fragmentation, 4.7 g of cDNA was 
hybridized on the GeneChip Human Gene 2.0 ST Array using the GeneChip 
Hybridization Oven 645. GeneChips were washed and stained in the GeneChip Fluidics 
Station 450. GeneChips were scanned using the GeneChip Scanner 3000 7G. Data were 
analyzed with Expression Console v1.4 (Affymetrix) and Transcriptome Analysis 
Console v3.0 (Affymetrix). Robust multichip average (RMA) was used as a 
summarization algorithm. Value definition was log2 GC-RMA signal. Microarray data 
were analyzed using GeneSpring software. The complete data set may be accessed at 
NCBI-Gene Expression Omnibus (accession GSE 84723). 
 
2.5. Cell culture 
 Human ovarian cancer cell lines SKOV-3, ES-2, OVCAR-3, and RMG-1 
were obtained from the American Type Culture Collection (ATCC, Manassas, VA). 
Cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum 
(FBS; ICN Biochemicals, Irvine, CA), 100 U/ml penicillin G, and 100 µg/ml 
streptomycin (Invitrogen, Carlsbad, CA) in a humidified atmosphere of 5% CO2 at 
37°C. 
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2.6. Generation of stably transfected cell lines 
 The Hsa-miR-135a coding region was PCR-amplified from 293T genomic 
DNA using the following primers: miR-135a_Fw_735, 5-gcgaagcttAGGCCTCGCTGT 
TCTCTATGG-3; miR-135a_Rv, 5-catggatccTGTCCCCGCCGTGCGCCACGG-3. 
The fragment was inserted into HindIII/BamHI sites of the pmR-ZsGreen-1 (Takara, 
Clontech) vector. Expression vectors for pmR-ZsGreen1/miR-135a or pmR-ZsGreen1 
(as control) were transfected into SKOV-3, ES-2, OVCAR-3, and RMG-1 cells using 
Lipofectamine 2000 (Invitrogen). At 48–72 h post-transfection, the culture medium was 
changed to RPMI-1640 supplemented with 10% FBS and puromycin to select 
transfected cells. 
 
2.7. WST-8 assay 
The effect of miR-135a-3p on SKOV-3, ES-2, OVCAR-3, or RMG-1 cell 
viability was determined using the WST-8 assay kit (Cell Counting Kit-8, Dojindo, 
Kumamoto, Japan). Stable transfected SKOV-3 and ES-2 cell lines were seeded in 
96-well plates and allowed to grow for 48 h. Freshly prepared anticancer drugs 
paclitaxel (PTX; 10 nM, 100 nM, or 1000 nM) and cisplatin (CDDP; 10 µM, 20 µM, 30 
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µM, or 100 µM) were added to each well. After 48 h, WST-8 was added to each well for 
1 h before the first measurement. Absorbance at 450 nm was measured using a 
microplate reader according to the manufacturer’s instructions. 
 
 
2.8. Antitumor effects of miR-135a-3p in a mouse xenograft model 
 Subconfluent cell cultures were detached from plates with trypsin-EDTA. A 
total volume of 250 µl containing 1×106 cells suspended in serum-free RPMI-1640 was 
injected subcutaneously into 4-week-old nude mice (Charles River Laboratories Japan 
Inc., Yokohama, Japan). To assess the inhibitory effects of miR-135a-3p on tumor 
growth, cells transfected with miR-blank or miR-135a-3p were injected subcutaneously 
and the tumor volume was estimated from two-dimensional tumor measurements as 
follows: tumor volume (mm3) = (length×width2)/2. The animal protocol was approved 
according to the guidelines of the Animal Care of Fukuoka University (Approval No. 
1306662) and the Ethics committee. Animals were observed daily. Humane endpoints 
were defined as loss of more than 10% of body mass, tumor diameter greater than 20 
mm, or inability to ambulate or rise for food and water. If animals reached these 
endpoints they were euthanized by exsanguination. Animal surgery and euthanasia 
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using decapitation were performed under inhalation (isoflurane) anesthesia, and all 
efforts were made to minimize suffering. 
 
2.9. Target gene profiling 
Microarray data were analyzed using GeneSpring software. A fold change 
<3.0 or >3.0 was considered statistically significant. Hierarchical clustering analysis 
was used to organize the genes based on similarities in expression profiles. 
Target prediction for miR-135a-3p was also performed using the algorithms 
Targetscan (http://www.targetscan.org/vert_71/), miRDB (http://mirdb.org/miRDB/), 
and miRanda (http://www.microrna.org/microrna/home.do) in terms of base sequence. 
All prediction processes were conducted using custom-written executable files that 
computed the parameters between miRNAs and mRNAs based on inherent algorithms 
and set thresholds. The thresholds for the algorithms were context score ≤0.4 for 
Targetscan; Target score ≥60 for miRDB; and seed misSVR score >1.25 for miRanda. 
 
2.10. Statistical analysis 
 All experiments were carried out in triplicate and quantitative values were 
expressed as means ± SEM. Cutoff values of miR-135a-3p, miR-630, and miR-1207 
17 
 
expression were taken as the medians of expression levels in serum from 98 patients 
with ovarian cancer. The statistical significance of differences among the groups was 
assessed using the Mann–Whitney U test. Correlation was tested and presented as 
Pearson’s correlation coefficient (r). The survival fraction was calculated by the 
Kaplan–Meier test with 95% confidence intervals computed by the asymmetrical 
method using the log-rank test. A value of P<0.05 was considered statistically 
significant. Analysis was performed using GraphPad Prism (GraphPad Software, La 
Jolla, CA). 
 
3. Results 
3.1. Serum miRNA expression profiles associated with prognosis in ovarian cancer 
patients  
To identify serum biomarkers associated with clinical prognosis of ovarian 
cancer, we compared serum miRNA expression changes between group A (poor 
prognosis) and group B (favorable prognosis). Three miRNAs, miR-135a-3p, miR-630, 
and miR-1207, that showed significant differences in the miRNA expression index in 
serum samples between Group A and B were identified using miRNA array analysis 
(Table 1). To assess their clinical significance, we calculated the median value for each 
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in 98 ovarian cancer patients and examined PFS in patients with low or high expression 
of miRNA based on each median value. The median expression index of miR-135a-3p, 
miR-630, and miR-1207 was 0.406, 0.000403, and 0.211, respectively, with the former 
markedly enhanced compared with the other two (Supplementary Figure 1). Patients 
harboring high miR-135a-3p expression showed a significantly favorable prognosis 
compared with those harboring low expression; in contrast, expression of miR-630 or 
miR-1207 was not associated with clinical prognosis (Figure 1). These results suggest 
that miR-135a-3p might be considered a biomarker in ovarian cancer. 
3.2 Clinical significance of miR-135-3p in ovarian cancer patients  
To provide clinical insights into miR-135a-3p expression in ovarian cancer, we 
examined the miR-135a-3p expression index in serum, peritoneal fluid, or tissue 
samples of patients with ovarian cancer, ovarian cysts, normal ovaries, or endometrial 
cancer. This serum index was significantly decreased in ovarian cancer patients 
compared with those with ovarian cysts or normal ovaries (Figure 2A), while the tissue 
sample index was significantly reduced in ovarian cancer patients compared with those 
with normal ovaries (Figure 2B), and the peritoneal fluid sample expression index was 
significantly suppressed in ovarian cancer patients compared with those with ovarian 
cysts or early endometrial cancer (Figure 2C). In any patient, the miR-135a-p 
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expression level in peritoneal fluid samples was approximately 10 times higher than in 
serum samples, and 100 times higher than in tissue samples. In 47 ovarian cancer 
patients, the serum miR-135a-3p expression index was significantly correlated with that 
in tissue samples (P<0.05, r=0.3671) (Figure 2D). In 17/47 ovarian cancer patients, the 
serum miR-135a-3p expression index was also significantly associated with that in 
peritoneal samples (P<0.05, r=0.5703) (Figure 2E). However, in all 47 ovarian cancer 
patients, the serum miR-135a-3p expression index was not correlated with the value of 
CA125 in serum samples (Supplementary Figure 2). These findings suggest that 
miR-135a-p is produced in the cells and excreted into the peritoneal fluid, and may 
contribute to cancer progression. 
3.3. Contribution of miR-135a-p to cancer progression 
To gain insights into miR-135a-p as a therapeutic target for ovarian cancer, we 
examined tumor activity including cell proliferation, chemosensitivity, and tumor 
formation after transfection of miR-135a-3p or miR-blank into ovarian cancer cells. 
Cells transfected with miR-135a-3p had marked expression of mR-135a-3p, compared 
with cells transfected with miR-blank (all P<0.05) (Figure 3A). Transfection of 
miR-135a-3p into SKOV-3, ES-2, OVCAR-3, or RMG-1 cells significantly suppressed 
cell viability compared with miR-blank transfection (all P<0.05) (Figure 3A). 
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Transfection of miR-135a-3p into SKOV-3 or ES-2 cells significantly reduced cell 
viability for each concentration of CDDP or paclitaxel compared with transfection of 
miR-blank (all P<0.05) (Figure 3B). In SKOV-3 cells, miR-135a-3p transfection 
completely blocked tumor formation compared with miR-blank (Figure 3C). In ES-2 
cells, transfection of miR-135a-3p markedly suppressed tumor growth compared with 
miR-blank (Figure 3C). These findings indicate that miR-135a-3p attenuates malignant 
properties of ovarian cancer cells, including cell proliferation, drug sensitivity, and 
tumor formation, suggesting that miR-135a-3p itself may be considered a therapeutic 
agent in nucleic acid medicine for ovarian cancer. 
3.4. Identification of genes regulated by miR-135a-3p expression in ovarian cancer 
To identify the genes and specific pathways altered by miR-135a-3p expression, 
we examined gene expression changes between cells transfected with miR-135a-3p and 
miR-blank and then analyzed the specific pathways affected. Comparison of common 
gene expression changes in SKOV-3 and ES-2 cells after transfection with miR-135a-3p 
or miR-blank identified six genes that showed >3-fold expression changes in cells 
transfected with miR-135a-3p compared with miR-blank as candidate targeted genes 
(Group 1) (Figure 4A and Table 2). Additionally, genes showing >2-fold change 
between cells transfected with miR-135a-3p and miR-blank were also analyzed 
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according to specific pathways. A total of 20 genes showed >2-fold upregulation and 58 
genes showed >2-fold downregulation in cells transfected with miR-135a-3p compared 
with miR-blank. However, analysis of specific pathways revealed that no more than 
three genes were involved in the same pathway. 
To confirm the expression of the six genes showing >3-fold change in 
expression in miR-135a-3p-transfected cells, we examined the expression index of each 
gene in SKOV-3 or ES-2 cells transfected with miR-135a-3p or miR-blank using 
RT-PCT. Expression of all six genes was reduced by the introduction of miR-135a-3p 
compared with miR-blank in both ovarian cancer cell lines (all P<0.05) (Figure 4B). To 
verify the clinical importance of these genes in ovarian cancer, we examined their 
expression in tissue samples of 20/47 patients with ovarian cancer and five patients with 
normal ovaries using RT-PCR. For five genes in Group 1, the expression index of 
BIRC3, GAGRA3, and SPANXB1/SPANXB2 was significantly increased in ovarian 
cancer patients compared with patients with normal ovaries (all P< 0.05), whereas no 
expression of NCAM2 or TMPRSS15 was found in ovarian cancer patients or those with 
normal ovaries (Figure 5A). 
Through combination analysis of Targetscan, miRDB, and miRanda for the 
sequence of miR-135a-3p, six genes were identified as theoretical targets for 
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miR-135a-3p (Group 2) (Supplementary Figure 3 and Supplementary Table 3). To 
assess the clinical importance of these genes in ovarian cancer we examined their 
expression as described above for the six genes. PPP2R2B expression was significantly 
increased in ovarian cancer patients compared with patients with normal ovaries 
(P<0.05) (Figure 5B). No significant difference was observed in the expression of SYT4, 
IL1RAP, RERG, C9orf152, or PAIP1 between ovarian cancer patients and those with 
normal ovaries (Figure 5B). According to these findings, miR-135a-3p appears to 
directly regulate PPP2R2B expression and indirectly regulate that of BIRC3, GAGRA3, 
or SPNAXB1/SPANXB2, resulting in the progression of ovarian cancer. 
 
4. Discussion 
In this study, we demonstrated that miR-135a-3p is abundantly present in cells 
and biofluids, including serum and peritoneal fluid, and that miR-135a-3p suppresses 
malignant properties in ovarian cancer. It is therefore plausible that miR-135a-3p, which 
is already recognized as a serum biomarker and a nucleic acid agent for cancer therapy, 
is a promising miRNA for the treatment of ovarian cancer. 
miR-135a-3p expression in peritoneal fluid was enriched up to 100-fold 
compared with that in cells or sera of any patient. Additionally, its expression was 
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attenuated with the increase in peritoneal fluid during ovarian cancer progression. 
Accordingly, it is possible that miR-135a-3p affects the circulation of peritoneal fluid. 
Many studies have investigated the relationship between miR-135a-5p and cancer 
(17-23), but few concern miR-135a-3p (24,25). miR-135a-5p has often been reported to 
function as a potential tumor suppressor (17-23). In prostate cancer cells, miR-135a-3p 
was shown to mimic the enhanced apoptosis induced by death receptor 5 with respect to 
increased PARP cleavage, Bax expression, and the number of TUNEL-positive cells 
following co-treatment with Tanshinone I and TRAIL (25). Our present study indicates 
that miR-135a-3p may also have antitumor activities in ovarian cancer. Human 
miR-135a is encoded by two genes located on different chromosomes that produce 
identical active sequences (chromosomes 3 and 12 for miR-135a1 and miR-135a2, 
respectively). Additionally, miR-135a-3p and miR-135a-5p are produced from the same 
transcript. Although contradictory results have been reported concerning the effects of 
miR-135a-3p and miR-135a-5p on cancer progression, the genes targeted by miR-135a 
may themselves be involved in cell growth. 
  Combination analysis of the miR-135a-3p sequence by Targetscan, miRDB, 
and miRanda predicted that miR135a-3p might directly regulate the expression of six 
genes (Supplementary Figure 4). We showed that PPP2R2B expression was 
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significantly increased in ovarian cancer compared with normal ovaries. PPP2R2B 
encodes a regulatory subunit of protein phosphatase 2A, which has been implicated in 
breast tumorigenesis and progression (26-28). PPP2R2B was reported to contribute to 
HER-2 signaling and enhanced expression of estrogen receptor in breast cancer (26, 27). 
Our screen of transfected ovarian cancer cells identified five genes as putative targets 
for miR-135a-3p. We further showed that the expression of BIRC3, GABRA3, and 
SPANXB1/SPANXB2 was significantly upregulated in ovarian cancer compared with 
normal ovaries. BIRC3 belongs to the inhibitor of apoptosis family of proteins and 
plays pivotal roles in the regulation of nuclear factor-kB signaling and apoptosis (29). 
Various somatic alterations of BIRC3 have been identified in lymphoid malignancies 
and many epithelial tumors, including ovarian cancer (30, 31). GABA is an inhibitory 
neurotransmitter that functions through two types of GABA receptors: ionotropic 
receptors including GABAA and GABAC receptors, and the metabotropic GABAB 
receptor (32, 33). GABRA3, of the GABAA group of receptors, is normally expressed 
in adult brain, and is inversely correlated with breast cancer survival; it activates the 
AKT pathway to promote breast cancer cell migration, invasion, and metastasis (34). 
GABRA3 enhances lymphatic metastasis in lung adenocarcinoma through activating the 
JNK/AP-1 signaling pathway (35). The testis-specific gene SPANXB is normally 
25 
 
expressed only in spermatozoa. Although sporadic SPANXB expression has previously 
been demonstrated in cancer cell lines and hematologic malignancies, the function of 
SPANXB or related genes is poorly understood (36, 37). We also showed that 58 genes 
were suppressed and 30 upregulated in our gene profiling, suggesting that miR-135a-3p 
can directly or indirectly regulate the expression of many oncogenic or suppressive 
genes in ovarian cancer progression. 
DNA and RNA are simple linear polymers that have moved into the realm of 
stand-alone therapeutic agents for a variety of human diseases (38). Several types of 
RNA molecules with complex biological functions, including mRNA, transfer RNA, 
miRNA, and short interfering (si)RNA, have been discovered (38), while major 
chemical modifications in siRNA and miRNA have been identified, including the ribose 
2-OH group modification, locked and unlocked nucleic acids, and phosphorothioate 
modification, leading to a diverse range of therapeutic applications for human diseases 
(39). On the basis of this, clinical trials of siRNA- and miRNA-based drugs have 
already been initiated (39, 40). In this study, miR-135a-3p can be regarded as an 
integrated therapeutic agent with multiple targets for ovarian cancer therapy, and is 
probably associated with the retention of peritoneal fluid, chemoresistance, and 
tumorigenesis in ovarian cancer. In ovarian cancer patients, the presence of ascites is 
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essentially treated through management of underlying disease. Once chemoresistance 
has developed, however, intractable ascites can be a major problem involving several 
molecules (41). Accordingly, intravenous or subcutaneous administration of 
miR-135a-3p mimics may improve the clinical prognosis in peritonitis carcinomatosa 
induced by ovarian cancer through the enhancement of chemosensitivity or the 
reduction of ascites. 
In conclusion, the iR-135a-3p expression index is suitable for application as a 
biomarker in treatment of ovarian cancer, and miR-135a-3p mimics are promising 
agents for ovarian cancer therapy. 
(4044 words) 
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Figure Legends 
 
Figure 1. Progression-free survival in ovarian cancer patients with high or low 
expression index of miR-135a-3p (A), miR-630 (B), or miR-1207 (C). * P<0.05 
Figure 2. Clinical significance of miR-135a-3p in patients with ovarian cancer, other 
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gynecologic diseases, and normal ovary. Expression index of miR-135a-3p in serum 
samples among patients with ovarian cancer, ovarian cyst, and normal ovary (A). 
Expression index of miR-135a-3p in tissue samples between patients with ovarian 
cancer and normal ovary (B). Expression index of miR-135a-3p in peritoneal fluid 
samples among patients with ovarian cancer, ovarian cyst, and endometrial cancer (C). 
Expression index of miR-135a-3p between serum and tissue samples in 47 patients with 
ovarian cancer (D), and between serum and peritoneal fluid samples in 17 patients with 
ovarian cancer (E). R indicates the correlation index. Data are mean ± SEM, * P<0.05 
Figure 3. Assessment of antitumor properties of miR-135a-3p in ovarian cancer. 
Alterations in cell viability and the expression index of miR-135a-3p induced by 
transfection of miR-135a-3p or miR-blank into SKOV-3, ES-2, OVCAR-3, or RMG-1 
cells (A). Alteration in cell viability of SKOV-3 or ES-2 cells transfected with 
miR-135a-3p or miR-blank in the presence of different concentrations of CDDP or 
paclitaxel (B). Tumor formation on NOD/SCID mice by SKOV-3 or ES-2 cells 
transfected with miR-135a-3p or miR-blank (C). Data are mean ± SEM, * P<0.05. 
Figure 4. Expression changes in genes targeted by miR-135a-3p in ovarian cancer. 
Gene profiling between SKOV-3 and ES-2 cells transfected with miR-135a-3p or 
miR-blank (A). Alterations in the expression of each targeted gene in SKOV-3 or ES-2 
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cells transfected by miR-135a-3p or miR-blank (B). Data are mean ± SEM, * P<0.05. 
Figure 5. Alterations in the expression of each targeted gene in patients with ovarian 
cancer or normal ovary (A). Alterations in the expression of each targeted gene 
predicted by Targetscan, miRDB, and miRanda in patients with ovarian cancer or 
normal ovary (B). Data are mean ± SEM, * P<0.05. 
 
Supplementary Figure 1. Alterations in the expression index of miR-135a-3p (A), 
miR-630 (B), or miR-1207 (C) in 98 patients with ovarian cancer. 
Supplementary Figure 2. Relationship between the expression index of miR-135a-3p 
and serum CA125 in 47 patients with ovarian cancer. R indicates the correlation index. 
* P<0.05. 
Supplementary Figure 3. Alterations in body weight of NOD/SCID mice with 
xenograft tumors of SKOV-3 or ES-2 cells transfected with miR-135a-3p or miR-blank. 
* P<0.05. 
Supplementary Figure 4. Profiling of genes targeted by miR-135a-3p through 
prediction using Targetscan, miRDB, and miRanda. 
Supplementary Table 1. Clinical characteristics of patients with primary OVCA for 
microarray analysis. 
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Supplementary Table 2. Clinical characteristic of the OVCA patients for RT-PCR 
analysis. 
Supplementary Table 3. The target prediction by Tagetscan, miRDB and miRanda  
(Group 2)  
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Table 1     
miRNAs as a candidate of biomarker in primary OVCA. 
 
 
 
 
Symbol P-value Fold change 
hsa-miR-135a-3p 0.0104 0.673 
hsa-miR-630 0.0097 0.405 
hsa-miR-1207 0.0236 1.266 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Table 2     
The target candidate by microarray analysis (Group1) 
 
 
 
 
Gene symbol Gene name Fold change 
BIRC3 Baculoviral IAP repeat containing 3 -3.3256896 
GABRA3 Gamma-aminobutyric acid type A receptor alpha 3 -3.3673131 
SPANXB1/2 SPANX family member B1/2 -5.5325503 
TMPRSS15 Transmembrane protease, serine 15 -10.862935 
NCAM2 Neural cell adhension molecule 2 -11.769233 
Strongest positive and negative correlation between the most expressed messenger RNA 
( top upregulated and downregulated genes). In sequence : Gene symbol, gene name, 
average fold change expression in cells with miR-135a-3p overexpression compared to 
miR-blank control. 
 
 
 
 
 
 
 
 
  
 
  
  
  
  
  
  
  
  
  
  
 
